medigraphic.com
Colegio de Medicina Interna de México.

2008, Number 3

<< Back Next >>

Med Int Mex 2008; 24 (3)

HIV-AIDS in a second level hospital

Martínez MJA, Esquivel MCG

Language: Spanish
References: 31
Page: 193-197
PDF size: 155.49 Kb.


ABSTRACT

Background: Acquired immunodeficiency syndrome is caused by a retrovirus that affects T-helper lymphocyte sub-populations. Montagnier et al first isolated human immunodeficiency virus (VIH) in 1983, and in 1984 CD4 was identified as its receptor molecule. HIV infection and acquired immunodeficiency syndrome are a world health problem.
Objective: To establish HIV-AIDS situation in a second level hospital.
Material and methods: 126 files of patients with HIV-AIDS (positives to Western Blot test) were reviewed (85 complete), from both sexes, and older than 18 years. Exclusion criteria: consultation desertion, incomplete files.
Results: Age average was 42; 71 (83.5%) were male. Sixty percent has basic education, 50% was employed; 51.8% was single, and 22.4% married; 40% assumed itself as homosexual and 40% as heterosexual. Infection was sexual in 95%; 48.1% has one to three years of evolution, 35.3% four to six years, and 16.5% seven to ten years. All cases were treated with antiretroviral (viral load 45%; and CD4 45.9%). Prevalence was 0.053%, and mortality 10.6%, yearly.
Conclusions: Prevalence was low (lower than national), and there was male predominance. Viral loads and CD4 should be performed in all cases, and genotype studies in specific cases.


REFERENCES

  1. Carrillo Maravilla E, Villegas Jiménez A. El descubrimiento del VIH en los albores de la epidemia del SIDA. Rev Invest Clin 2004;56(2):130-3.

  2. Pérez Saleme L, Hernández Tepichin G. Epidemiología de la infección por virus de la inmunodeficiencia adquirida: veinte años de experiencia. Rev Invest Clin 2004;56(2):134-42.

  3. ONUSIDA. Situación de la epidemia del VIH-SIDA. Diciembre de 2005. www.unaids.com

  4. CONASIDA. Guía de manejo antirretroviral de las personas que viven con el VIH-SIDA. 2005-2006.

  5. CENSIDA. Panorámica epidemiológica del VIH-SIDA en México: 2005. www.ssa.gob.mx/censida/

  6. Wood E, Hogg RS, Yip B, Harrigan R, Montaner JS. Using baseline CD4 cell count and plasma HIV RNA to guide the iniciation of highly active antiretroviral therapy. Rev Invest Clin 2004;56(2):232-6.

  7. Yenni PG, Hammer SM, Hirsch MS, Saag MS, et al. Treatment for adult HIV infection. JAMA 2004;292(2):251-65.

  8. Soto Ramírez LE, Pérez Saleme L, Hernández Tepichin G, Sierra Madero J y col. Guía para el tratamiento antirretroviral de las personas adultas que viven con VIH-SIDA. Rev Invest Clin 2004;56(2):253-71.

  9. Sierra Madero JG, Franco San Sebastián D. Tratamiento antiviral en el manejo de la infección por VIH. ¿En dónde estamos y hacia dónde vamos? Rev Invest Clin 2004;56(2):222-31.

  10. Tubiana R, Katlama C, Calvez V, Mohand H, Autran B. Longlasting recovery in CD4 T-cell function and viral-load reduction alter highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.

  11. Phillips AN, Staszewski S, Weber R, Kira O, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001;286:2568-97.

  12. Magis Rodríguez C, Bravo García E, Uribe Zúñiga P. Dos décadas de la epidemia del SIDA en México. CENSIDA. www.ssa.gob.mx/censida/

  13. Gutiérrez JP, López Zaragoza JL, Valencia Mendoza A, Pesqueira E, y col. Haciendo frente a la epidemia de VIH-SIDA en México: ¿una respuesta organizada? Rev Invest Clin 2004;56(2):242-52.

  14. Martín del Campo Rodríguez LE, Sifuentes Osornio J. Infecciones oportunistas en el síndrome de inmunodeficiencia adquirida: la historia en México a 20 años de la epidemia. Rev Invest Clin 2004;56(2):169-80.

  15. Sánchez Vargas LO, Ortiz López NG, Villar M, Moragues MD, et al. Point prevalence microbiology and antifungal susceptibility patterns of oral candida isolates colonizing or infecting Mexican HIV-AIDS patients and healthy persons. Rev Iberoam Micol 2005;2:83-92.

  16. Berenguer J, Laguna F, López Aldeguer J, Moreno S y col. Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA. Enferm Infecc Microbiol Clin 2004;3:160-76.

  17. Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, et al. Factors associated with the development opportunistic infections in HIV-1 infected adults with high CD4+ cell counts: a EuroSIDA study. J Infect Dis 2006;194(5):633-41.

  18. Secretaría de Salud en el estado de Coahuila. Jurisdicción sanitaria VI. Epidemiología. Reporte de casos y defunciones VIH-SIDA 2004-2005.

  19. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283(1):74-80.

  20. Ponce de León A. Una visión global y local de la relación entre la infección por el virus de la inmunodeficiencia humana y la tuberculosis. Rev Invest Clin 2004;56(2):181-5.

  21. Girardi E, Antonucci G, Vanacore P, Palmieri F, et al. Tuberculosis in HIV-infected persons in the contest of wide availability of highly active antiretroviral therapy. Eur Respir J 2004;1:11-17.

  22. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.

  23. Fellay J, Boubaker K, Ledergerber BL, Bernasconi E, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet 2001;358:1322-7.

  24. Yarashesid KE, Tebas P, Clayton S, Coleman T, et al. Visceral adiposite, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003;5(4):899-905.

  25. Rodríguez Carranza SI, Aguilar Salinas CA. Anormalidades metabólicas en pacientes con infección por VIH. Rev Invest Clin 2004;56(2):193-208.

  26. Mehta R, Loredo B, Sañudo ME, Hernández Jiménez S y col. Epidemiología de las anormalidades metabólicas en pacientes con infección por VIH. Rev Invest Clin 2004;56(2):209-21.

  27. Zúñiga J, Vargas Alarcón G, Salgado N, Flores C y col. Los factores genéticos determinantes de la resistencia a la infección por VIH y del control de la progresión al SIDA: implicaciones sobre la patogénesis y las estrategias terapéuticas para la erradicación del VIH. Una revisión. Rev Invest Clin 2004;56(2):284-95.

  28. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002-11.

  29. Little SJ, Holte S, Routy JP, Daar ES, et al. Antiretroviral-drug resistence among patients recently infected with HIV. N Engl Med 2002;347:385-94.

  30. Weinstein MC, Goldie S, Losina E, Cohen CJ, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-50.

  31. Novak RM, Chen L, MacArthur RD, Baxter JD, et al. Prevalence of antiretroviral drug resistence mutations in chronically HIV infected, treatment-naive patients: implications for routine resistence screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40(3):468-74.




2020     |     www.medigraphic.com